(NASDAQ: LPCN) Lipocine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Lipocine's earnings in 2026 is -$9,627,505.On average, 4 Wall Street analysts forecast LPCN's earnings for 2026 to be -$14,370,164, with the lowest LPCN earnings forecast at -$13,949,702, and the highest LPCN earnings forecast at -$14,639,522. On average, 3 Wall Street analysts forecast LPCN's earnings for 2027 to be -$12,285,373, with the lowest LPCN earnings forecast at -$11,803,594, and the highest LPCN earnings forecast at -$12,646,708.
In 2028, LPCN is forecast to generate -$7,073,397 in earnings, with the lowest earnings forecast at -$6,796,009 and the highest earnings forecast at -$7,281,438.